MCTL THERAPY
FOR LUNG CANCER
Personalised neoantigen-reactive T cell therapy — harnessing the patient's own immune cells, trained to recognise mutations unique to their tumour.
analyticsAt a Glance
- check_circleMCTL therapy uses patient-derived T cells expanded against tumour-specific mutant peptides (neoantigens)
- check_circleEach MCTL product is personalised — manufactured from the patient's own blood and tumour mutational profile
- check_circleBeing evaluated in NSCLC as monotherapy and in combination with checkpoint inhibitors and chemotherapy
- check_circleCancerFax connects lung cancer patients with Chinese academic centres developing MCTL clinical protocols
What Is MCTL Therapy?
MCTL therapy — Mutant-peptide Cytotoxic T Lymphocyte therapy — is a form of personalised adoptive cell therapy in which cytotoxic T lymphocytes (CTLs) are isolated from a patient's blood, expanded in vitro, and specifically activated or selected against mutant peptides (neoantigens) derived from the patient's own tumour. The resulting MCTL product is a population of T cells enriched for tumour-specific reactivity — returned to the patient as an infusion.
“MCTL therapy does not use a generic immune cell product — it uses T cells trained specifically against the mutations that make your tumour unique.”
What Are Neoantigens?
Neoantigens are peptides derived from tumour-specific somatic mutations — protein fragments that are displayed on the surface of cancer cells but not on normal cells. Because they are foreign to the immune system, neoantigen-reactive T cells can theoretically attack tumour cells with high specificity and minimal on-target/off-tumour toxicity. The first step in MCTL manufacturing is identifying these mutations from the patient's tumour by next-generation sequencing.
How MCTL Differs from Standard Adoptive Cell Therapy
Unlike TIL (tumour-infiltrating lymphocyte) therapy — which expands all T cells from tumour tissue — MCTL selectively expands or activates T cells with confirmed reactivity against specific mutant neoantigens. Unlike CAR-T, MCTL does not require genetic engineering of T cells. It is a precision enrichment of naturally occurring tumour-reactive T cell clones.
How MCTL Is Manufactured: The Personalised Process
MCTL manufacturing is a multi-step personalised process — each batch is unique to the individual patient. The complexity and time required mean MCTL is not suitable for rapidly progressing disease without bridging therapy.
Step 1: Tumour Sequencing and Neoantigen Identification
The patient's tumour tissue (biopsy or surgical specimen) undergoes whole exome sequencing (WES) or targeted deep sequencing alongside matched normal tissue sequencing. Somatic mutations are identified and computationally filtered to predict which mutant peptides bind strongly to the patient's HLA (human leukocyte antigen) molecules — the cell surface presentation system.
Step 2: T Cell Isolation, Expansion, and Activation
Peripheral blood mononuclear cells (PBMCs) are collected from the patient by leukapheresis. T cells are stimulated with the identified neoantigen peptides — those that respond (by proliferating or producing IFN-γ) are selected or preferentially expanded over 2–6 weeks in a GMP-compliant cell manufacturing facility.
NSCLC and Neoantigen Therapy: Clinical Context
Understanding the biological rationale and clinical landscape for MCTL therapy in lung cancer requires context about NSCLC mutational burden and the immunotherapy response setting.
- ~10Median number of predicted neoantigens per NSCLC tumour targetable by MCTLNSCLC is a relatively high-TMB (tumour mutational burden) cancer — particularly in smokers — generating a pool of somatic mutations from which actionable neoantigens for MCTL production can be identified. Smoker-associated NSCLC typically has higher neoantigen burden than never-smoker EGFR/ALK-driven tumours.
- 20–25%Long-term response rate to anti-PD-1 monotherapy in NSCLC (unselected)The limitations of checkpoint inhibitor monotherapy — active in only ~20–25% of unselected NSCLC patients — provide the therapeutic rationale for combining immune cell therapy approaches that may have complementary mechanisms of tumour killing.
- 3–6 weeksTypical MCTL manufacturing timeline from leukapheresis to infusion-ready productThe personalised manufacturing process requires 3–6 weeks from blood collection to a quality-tested, infusion-ready MCTL product — necessitating bridging therapy for patients with actively progressing disease during manufacture.
The MCTL Therapy Patient Journey
For patients being considered for MCTL therapy, the process involves multiple coordinated steps — from molecular profiling to infusion and post-treatment monitoring.
- 1
Molecular Profiling: WES and HLA Typing
The patient's tumour tissue and matched blood undergo whole exome sequencing to identify somatic mutations. HLA typing (the patient's specific immune presentation molecules) is performed from blood. Together these data inputs drive neoantigen prediction — the computational heart of MCTL design.
- 2
Neoantigen Prediction and Peptide Selection
Bioinformatics pipelines identify which mutant peptides are most likely to bind the patient's HLA molecules with sufficient affinity to activate T cells. Typically 10–20 candidate neoantigens are selected for laboratory validation before incorporation into the manufacturing process.
- 3
Leukapheresis: T Cell Collection
The patient undergoes leukapheresis — a 3–4 hour apheresis procedure collecting white blood cells (including T lymphocytes) from peripheral blood, without surgery or general anaesthesia. The collected PBMCs are sent to a GMP-certified cell manufacturing facility.
- 4
MCTL Manufacturing (3–6 Weeks)
T cells are cultured with the patient-specific neoantigen peptides in the presence of cytokines and co-stimulatory signals. Neoantigen-reactive clones expand preferentially. The product undergoes quality testing for sterility, viability, cell number, and tumour-specific reactivity before release.
- 5
Lymphodepletion and Infusion
A short course of lymphodepleting chemotherapy (typically fludarabine + cyclophosphamide, or non-myeloablative conditioning) is given 5–7 days before MCTL infusion — creating 'space' in the immune compartment to support engraftment of the infused T cells.
- 6
Post-Infusion Monitoring and Response Assessment
The patient is monitored for infusion-related adverse events, cytokine release syndrome (typically less severe than with CAR-T), and anti-tumour response. CT/PET imaging is performed at 6–8 weeks post-infusion to assess response. T cell persistence in the blood is tracked by immune monitoring assays.
MCTL vs Other Cell Therapy Approaches for Lung Cancer
Multiple adoptive cell therapy approaches are being developed for lung cancer — understanding how MCTL relates to TIL therapy and CAR-T helps clarify its positioning.
| Feature | MCTL Therapy | TIL Therapy | CAR-T (anti-tumour) | NK Cell Therapy |
|---|---|---|---|---|
| Cell source | Peripheral blood (leukapheresis) | Tumour tissue (resection/biopsy) | Peripheral blood (leukapheresis) | Peripheral blood or cord blood |
| Genetic engineering required? | No — natural T cell selection/expansion | No — non-engineered expansion | Yes — CAR construct inserted | Sometimes — NK activation/engineering |
| Tumour specificity | High — neoantigen-directed | Variable — mixed tumour-reactive and bystander T cells | High — target antigen-specific | Moderate — NK recognises stress ligands |
| Personalisation | Fully personalised per patient mutation profile | Personalised from patient tumour | Platform products available; some personalised | Allogeneic products possible |
| Manufacturing time | 3–6 weeks | 4–8 weeks | 3–5 weeks (autologous) | 2–4 weeks |
| Current status in NSCLC | Early clinical trials — Chinese academic centres leading | Phase I/II trials — most advanced in melanoma/cervical; lung ongoing | Limited solid tumour data — lung CAR-T preclinical/early clinical | Early trials — combination approaches |
| Main clinical hurdle in solid tumours | T cell persistence and tumour penetration | T cell exhaustion; tumour immunosuppression | Antigen heterogeneity; CAR T cell trafficking | Persistence and activity in immunosuppressive TME |
MCTL Therapy Eligibility: Favourable vs Challenging Factors
MCTL therapy eligibility in lung cancer is still being defined through clinical trials — these are the factors that currently influence candidacy based on published protocols and biological rationale.
Favourable for MCTL Candidacy
- High tumour mutational burden (TMB-high)NSCLC with TMB ≥10 mut/Mb — typically smoker-associated squamous or adenocarcinoma — generates a richer neoantigen pool for MCTL targeting. Higher TMB predicts more candidate neoantigens available for manufacturing.
- Prior platinum-based chemotherapy failureMost MCTL protocols target patients who have progressed on standard first- or second-line treatment — providing the treatment-line context most commonly studied in emerging cell therapy trials.
- Adequate performance status (ECOG 0–1) and organ functionThe conditioning chemotherapy and infusion process require adequate bone marrow reserve, renal, hepatic, and cardiac function — similar prerequisites to autologous stem cell transplantation.
Challenging Factors Requiring Discussion
- EGFR/ALK/ROS1-driven NSCLC — lower neoantigen burdenOncogene-driven NSCLC (EGFR-mutant, ALK-rearranged) tends to have lower TMB and fewer immunogenic neoantigens — potentially limiting the MCTL manufacturing yield and tumour-specific T cell frequency.
- Rapidly progressive disease during manufacturing windowThe 3–6 week manufacturing timeline requires disease stability or adequate bridging therapy. Patients with aggressive progression, large pleural effusions, or symptomatic CNS disease may not tolerate the manufacturing delay.
- Prior high-dose systemic immunosuppressionProlonged high-dose corticosteroids (e.g., for irAE management) or other immunosuppressants may reduce the quality and reactivity of collected T cells, potentially affecting manufacturing success.
Frequently Asked Questions
Common questions from lung cancer patients and families exploring MCTL therapy.
About MCTL Therapy for Lung Cancer
Is MCTL therapy approved for lung cancer?
MCTL therapy for lung cancer is currently investigational — it has not received regulatory approval (FDA, EMA, or NMPA) as a standard-of-care treatment. It is being evaluated in clinical trials at academic centres, primarily in China and select international sites. Access is through clinical trial enrolment or, in some cases, expanded access or compassionate use protocols at centres actively developing MCTL programmes. CancerFax can identify currently enrolling trials and assess eligibility.
How does MCTL therapy differ from pembrolizumab (Keytruda) or other immunotherapy?
Pembrolizumab and other checkpoint inhibitors work by releasing the brakes on existing T cells — relying on the patient already having tumour-reactive T cells that are being suppressed. MCTL therapy adds new tumour-specific T cells that are not present in sufficient numbers naturally. These mechanisms are theoretically complementary — which is why some MCTL trials combine T cell infusion with checkpoint inhibition. However, they are distinct agents with different mechanisms, side effect profiles, and evidence bases.
Can MCTL therapy be combined with my existing lung cancer treatment?
Combination approaches are among the most actively investigated aspects of MCTL therapy. Combinations under evaluation include MCTL + anti-PD-1/PD-L1 checkpoint inhibitors, MCTL + platinum-based chemotherapy, and MCTL following tumour reduction surgery. The rationale for combining MCTL with checkpoint inhibitors is that the checkpoint blockade may maintain the survival and function of infused neoantigen-reactive T cells that would otherwise become exhausted in the tumour microenvironment. Your eligibility for a specific combination protocol depends on your molecular profile and prior treatment history.
Where is MCTL therapy for lung cancer available and how do I access it?
MCTL therapy for lung cancer is primarily available through clinical trials at Chinese academic centres — including institutions affiliated with Fudan University, Peking University, and the Chinese Academy of Medical Sciences, which have active cell therapy research programmes. CancerFax maps your disease status and molecular profile against currently enrolling MCTL trials in China and internationally, coordinates the eligibility pre-screening process, and manages the full access pathway including medical visa and logistics if in-person participation is required.
More from the Lung Cancer Treatment Resource Library
Explore related guides on lung cancer treatments, cell therapy access, and CancerFax navigation services.
- ↑ Lung Cancer Treatment — Complete Guide
- TIL Therapy for Solid Tumours
- Second Opinions for CAR-T Therapy Eligibility: China vs Western Access
- The Molecular Second Opinion: NGS, Liquid Biopsy, and Missed Targeted Therapy
- How CancerFax Works: Cross-Border Cancer Treatment Navigation
- Cancer Second Opinions in China: Zhongshan, Fudan, and Sun Yat-sen
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore MCTL Therapy Access for Lung Cancer Through CancerFax
CancerFax reviews your NSCLC molecular profile, treatment history, and disease status to assess eligibility for MCTL therapy — and identifies access pathways including clinical trials and expanded access programmes at Chinese academic centres currently developing this treatment.
This content is for informational purposes only. MCTL therapy for lung cancer is currently investigational. Access is through clinical trials or approved expanded access protocols. Always consult a qualified oncologist before making treatment decisions.